Allarity Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Allarity Therapeutics has filed a definitive proxy statement with the Securities and Exchange Commission.
NASDAQ
Allarity Therapeutics is holding its annual meeting to vote on key proposals, including limiting officer liability and increasing shares for its equity incentive plan.
NASDAQ
Allarity Therapeutics is holding its 2024 Annual Meeting of Stockholders to vote on key proposals including a share decrease, a reverse stock split, and an amendment to limit officer liability.
NASDAQ
Allarity Therapeutics has postponed its 2024 annual meeting of stockholders, originally scheduled for July 26, 2024, to a later date to be determined by the Board.
NASDAQ
Allarity Therapeutics is holding its 2024 Annual Meeting of Stockholders virtually on July 26, 2024, to vote on several key proposals, including a share decrease, a reverse stock split, and an amendment to limit officer liability.
NASDAQ
Allarity Therapeutics is holding a special virtual meeting on April 1, 2024, to seek stockholder approval for an amendment to its equity incentive plan and a reverse stock split to maintain its Nasdaq listing.